IDEAYA Biosciences (NASDAQ:IDYA) First Half 2024 Results
Key financial results
- Net loss: $92.3 million (loss increased by 79% from H1 2023).
- Loss per share of $1.21 (a further deterioration from the loss of $0.98 in the first half of 2023).
All figures shown in the graph above refer to the last 12 months (TTM)
Insights into IDEAYA Biosciences results
An average sales growth of 64% per year is expected for the next three years. In the US biotech industry, however, growth of 23% is forecast.
Performance of American biotechnology industry.
The company’s shares fell 5.5 percent compared to the previous week.
Risk analysis
And what about the risks? Every company has them, and we have 2 warning signs for IDEAYA Biosciences You should know about this.
New: AI Stock Screeners and Alerts
Our new AI Stock Screener scans the market daily to uncover opportunities.
• Dividend powerhouses (3%+ yield)
• Undervalued small caps with insider purchases
• Fast-growing technology and AI companies
Or create your own from over 50 metrics.
Try it now for free
Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.
This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.
